Exhibit 99.1 Neurocrine Biosciences Reports Third Quarter 2025 Financial Results Achieved Total Net Product Sales of $790 Million Representing 28$687 Million Representing 12% Year- Over-Year Growth ® CRENESSITY (crinecerfont) Third-Quarter 2025 Net Product Sales of $98 Million with 540 Total New Patient Enrollment Start Forms ® SAN DIEGO, Oct. 28, 2025 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its fina ...